Poseida Therapeutics Inc
NASDAQ:PSTX

Watchlist Manager
Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc
NASDAQ:PSTX
Watchlist
Price: 9.5 USD -0.63% Market Closed
Market Cap: 926m USD

Relative Value

There is not enough data to reliably calculate the relative value of PSTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PSTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
9
vs Industry
55
Median 3Y
4.6
Median 5Y
3.6
Industry
8
Forward
6.2
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-4.3
Industry
23.5
Forward
-9.8
vs History
vs Industry
Median 3Y
-19.9
Median 5Y
-6
Industry
21.9
vs History
vs Industry
Median 3Y
-36
Median 5Y
-5.1
Industry
24.3
vs History
1
vs Industry
8
Median 3Y
3.6
Median 5Y
2.8
Industry
3.2
vs History
4
vs Industry
51
Median 3Y
1.9
Median 5Y
1.6
Industry
8.1
Forward
5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
31
Median 3Y
-2.1
Median 5Y
-2
Industry
5.9
Forward
-6
vs History
vs Industry
30
Median 3Y
-1.9
Median 5Y
-1.9
Industry
6.2
Forward
-7.9
vs History
vs Industry
32
Median 3Y
-6.4
Median 5Y
-2.6
Industry
7.7
vs History
vs Industry
29
Median 3Y
-5.6
Median 5Y
-2.4
Industry
6.3
vs History
1
vs Industry
16
Median 3Y
3
Median 5Y
3.5
Industry
5.6

Multiples Across Competitors

PSTX Competitors Multiples
Poseida Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Poseida Therapeutics Inc
NASDAQ:PSTX
925.4m USD 6.1 -15.2 -13.2 -12.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.5B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.1 33.1 57.3 58.9
P/E Multiple
Earnings Growth PEG
US
Poseida Therapeutics Inc
NASDAQ:PSTX
Average P/E: 191
Negative Multiple: -15.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.1
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Poseida Therapeutics Inc
NASDAQ:PSTX
Average EV/EBITDA: 40.1
Negative Multiple: -13.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
57.3
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Poseida Therapeutics Inc
NASDAQ:PSTX
Average EV/EBIT: 46.3
Negative Multiple: -12.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
58.9
N/A N/A